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Management and outcome
Background:Degenerative forms ofmitral valve diseases (MVDs) are very complex pathologies. Thus, it is difﬁcult to
make generalizations about the disease pathways or genetic risk factors contributing to these diseases. However, a
key role ofmetalloproteinases (MMPs) in their pathophysiology is emerging. Thus,we performed for theﬁrst time a
perspective study to assess eventual associations of some functional single nucleotide polymorphisms (SNPs) in
MMP-2 andMMP-9 geneswith theMVD risk, symptomseverity, and short- and long-term(4.8 years) complications.
Materials and methods: For this purpose, 90 patients and two control groups were genotyped for rs3918242,
rs243865, and rs2285053 MMP-2 and MMP-9 gene SNPs, and systemic levels of pro-atrial natriuretic peptide
(pro-ANP) and two enzymes were quantiﬁed and correlated to genotypes ofMMP-2 andMMP-9 SNPs studied. In
addition, associations between these SNPs and symptom severity and short- and long-term (4.8 years) complica-
tions were evaluated.
Results: Interestingly, rs3918242MMP-9 and rs2285053MMP-2 SNPs were signiﬁcantly represented in cases than
two control groups andwere associatedwith a higherMVD risk, as demonstrated using dominant/recessivemodels.
Cases stratiﬁed for NYHA symptoms and particularly those NYHA III+IV with rs3918242 CT+TT MMP-9 and
rs2285053CT+TT genotypes also showed higher severity related to signiﬁcant higher systemic levels of MMP en-
zymes and pro-ANP at enrolment and 4.8 follow-up times. In addition, cases with these genotypes and particularly
thoseNYHA III+IVhad a very signiﬁcant percentage of complications, particularly at the 4.8 follow-up. Surprisingly,
20% of patient controls developed MVD at 4.8-year follow-up and were carriers of these genotypes.
Conclusion: Thus, the associations observed seem to suggest that the two SNPs might represent useful biomarkers
and targets for preventing and monitoring MVDs and developing personalized treatments, consenting a more ap-
propriate management and outcome.
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Degenerative mitral valve diseases (MVDs) are a group of heart
valve pathologies, very common in European population andwith a sig-
niﬁcant increase in old people [1,2]. They, indeed,manifest after theﬁfth
decade of life and show a difﬁcult early diagnosis and a complex man-
agement, which represent the real challenge for clinicians [3]. Until
now, there is not a panel of diagnostic and prognostic biomarkers for
sporadic forms, and their physiopathology remains unclear. Echocardi-
ography evaluation represents until now unique “gold standard diag-
nostic” tool, even if it always reveals no appropriate for diagnosing
moderate forms [3–5]. This underlines the necessity of innovative bio-
marker tools to identify in molecular pathways associated with mecha-
nisms related to MVD pathogenesis. Recently, it is emerging that
Table 1
Patient's clinical and demographic characteristics
N=90
Variables Mean±SD
Age 66.01±10.8
Weight (kg) 68.7±12.1
Height (cm) 164.1±7.1
BSA 1.78±0.65
Ejection fraction (%) 57.4±8.34
Left atrium (cm2) 32.1±10.6
Left ventricular end-diastolic diameter (mm) 55.3±17.5
Left ventricular end-diastolic volume (ml) 112.8±35.4
Left ventricular end-systolic diameter (mm) 37.1±6.2
Left ventricular end-systolic volume (ml) 43.1±9.8
Pulmonary arterial systolic pressure (mmHg) 43.4±8.5
Patients Percentage (%)
Male 44 49
Female 46 51
Mortality 0 0
Emergencies 6 6.6
Dilatative cardiomyopathy 5 5.5
NYHA
Grade I-II 42 47
Grade III-IV 48 53
Smokers
Ex 30 33.4
Yes 20 22.2
No 40 44.4
Hypertension 56 62.2
Diabetes 12 13.3
Renal failure 7 7.7
Chronic obstructive
pulmonary disease
3 3.3
Atrial ﬁbrillation 39 43.3
Heart failure 3 3.3
Cerebrovascular disease 12 13.3
Mitral lesions
Regurgitation 56 62.2
Stenosis 14 15.5
Mixed 20 22.3
Mitral dysfunction
Chordae tendineae rupture 4 4.4
Calciﬁc degeneration 8 9
Prolapse 12 13.3
Tricuspid regurgitation
grades
Absent 12 36
Faint 32 39
Moderate 26 29
Severe 10 11.1
Pulmonary hypertension 65 72.2
Pharmacological treatment N (%) at preoperative time
treatment
N (%) at
follow-up time
Beta-blockers 50 69
Alpha-agonists 53 65
Sartans 51 68
Calcium antagonists 61 79
ACE inhibitors 40 45
Oral hypoglycemic agents 42 49
Antiaggregants 90 90
Antidyslipidemics 90 90
Diuretics 46 53
Data collected at the time of enrolment.
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Particularly, Levine and colleagues have recently underlined that
MVDs are the result of a ‘living valve’, which with advancing age
shows active changes mediated both by valvular endothelial and inter-
stitial cells and alterations in composition and turnover of elements of
extracellular matrix [6]. Accordingly, in surgically excised human myx-
omatous tissues, an overexpression of transforming growth factor-β cy-
tokine (TGF-β) pathway, an increased release of metalloproteinases
(MMPs), and down-expression of related inhibitors (TIMPs), responsi-
ble for degeneration of collagen and elastin structures, have been ob-
served [7–15]. Increased systemic and tissue levels of MMPs in cases
affected by degenerative sporadic MVDs andwith stenosis or regurgita-
tion complications have been also assessed [7–15]. In contrast, no ex-
haustive data about eventual associations between single nucleotide
polymorphisms (SNPs) inMMP genes and the risk of degenerative spo-
radic MVDs are reported until now in literature, since they are a very
limited number [16,17]. However, genetic association studies have the
potential to identifymolecular pathways as early diagnostic biomarkers
and targets. Ulterior evidence might also derive performing clinical
studies and correlations between polymorphisms and severity and
complications of these diseases.
Here, we performed for the ﬁrst time a 4.8-year prospective case–
control study in order to identify eventual associations of some func-
tionalMMP-2 andMMP-9 gene SNPs (known to determine an increased
release of these enzymes and higher susceptibility for several cardiovas-
cular diseases [18]; see Table 1S online supplementary materials) with
the MVD risk, severity, and short- and long-term follow-up complica-
tions. Thus, we enrolled a homogenous group of patients (N=90), all
affected by myxomatous degeneration and at late stage of disease,
when they were referred for mitral valve surgery (repair or replace-
ment), and a control group of patients (N=80), showing no degenera-
tive MVD at the time of its enrollment, but with a manifested
myxomatous mitral degeneration at the 4.8 follow-up time in 20% of
its components with NYHA I symptoms. Genotyping of the selected
SNPs and quantiﬁcation of systemic levels of MMP-2 and MMP-9 were
assessed for evaluating associations between the genotypes and MVD
risk and with the clinical disease phenotypes (i.e., circulating amount
of two enzymes, severity, and complications). For this last objective, sys-
temic levels of pro-atrial natriuretic peptide (pro-ANP) were also quan-
tiﬁed due to the emerging evidence suggesting a signiﬁcant association
between high circulating pro-ANP levels and severity and complication
of degenerativeMVDs [19–22]. These investigationsmight permit to ev-
idence whether the genetic variants selected and the circulating blood
levels of their molecules and the pro-ANP may be potential predictive,
diagnostic, and prognostic biomarkers. As a result, the management
strategies for the medical and surgical treatment of degenerative MVD
forms might become gene personalized. In addition, these insights
might suggest new treatment therapeutic options, such as use of agonist
and/or antagonists of TGF-β and ACE pathways and monoclonal anti-
bodies against MMP-2 and MMP-9.
2. Materials and methods
2.1. Enrolled patients: Clinical and demographic characteristics
Our study included 90 patients, all affected by myxomatous degen-
eration, 46 women and 44men,mean age 66±10.8 years, andwith de-
mographic and clinical characteristics shown in Table 1 (data collected
at the time of enrolment). They were randomly selected from patients
who underwent to mitral valve plastic surgery or replacement in the
Unit of Cardiac Surgery (Department of Surgery and Oncology, Univer-
sity of Palermo). Demographic, clinical, and echocardiographic data
(as described in detail in thenext paragraph) related to thepreoperative
and postoperative periods of hospitalization were also collected. All 90
patients were symptomatic before surgery and divided into two sub-
groups according to the degree of symptom's severity [3]. Precisely,the subgroupNYHA I+IIwas composed by 52 patients (58%) andNYHA
III+IV consisted of 38patients (42%) (see Tables 3a and 3b). All patients
were evaluated preoperatively by echocardiography, angiography and
underwent surgery (see paragraph 2.3). Mitral valve replacement
with mechanical or biological prosthesis was the principal surgery ap-
proach used than mitral valve plastic surgery applied only in few pa-
tients. Furthermore, they were also subjected to a 4.8-year follow-up,
in order to prospectively assess the echocardiographic data (see
Tables 3a and 3b), complications and to evaluate the weight of speciﬁc
MMP-9 and MMP-2 gene polymorphisms in the MVD outcome. To
Table 2
Clinical and demographic characteristics of the two control groups
Control patients Healthy controls
N=80 (%) N=168 (%)
Age (SD) 65.6±10.7 61±5.8
Men (%) 35 (44%) 81 (48%)
Women (%) 45 (56%) 87 (52%)
Body mass index (SD) 27.8±8.6 25.8±8.7
Comorbidity N (%) N (%)
Familiarity for coronaropathy 24 (30%) 40 (24%)
Smokers 46 (57.5%) 63 (38%)
Hypertension 28 (35%) 0 (0%)
Dyslipidemia 14 (17.5%) 0 (0%)
Diabetes mellitus 12 (15%) 0 (0%)
Renal failure 0 (0%) 0 (0%)
Ongoing cardiac diseases 0 (0%) 0 (0%)
Coronary atherosclerosis 0 (0%) 0 (0%)
Therapy N (%) N (%)
Beta-blockers 0 (0%) 0 (0%)
Alpha-agonists 0 (0%) 0 (0%)
Sartans 0 (0%) 0 (0%)
Calcium antagonists 0 (0%) 0 (0%)
ACE inhibitors 14 (17.5%) 0 (0%)
Oral hypoglycemic agents 12 (15%) 0 (0%)
Antiaggregants 28 (35%) 0 (0%)
Antidyslipidemics 0 (0%) 0 (0%)
Diuretics 28 (35%) 0 (0%)
364 C.R. Balistreri et al. / Cardiovascular Pathology 25 (2016) 362–370this aim, peripheral blood samples were also collected from patients in
order to assess the genetic background and to perform ELISA assays.
2.2. Enrolled controls: Clinical and demographic characteristics
Two control groups were also enrolled. The ﬁrst consisted of 80 pa-
tients (mean age 65.6±10.7 years; 45 women and 35 man) selected
among individuals who arrived in the outpatient department for
routine health screening for employment and without a manifested de-
generative MVD, as evidenced after meticulous physical and echocardi-
ography imaging examinations. Demographic and clinical features,
eventual comorbidities, and pharmacological treatments were collected
(see Table 2; data at the enrolment time). They were subjected to the
same follow-up (4.8 years) of the 90 patients. Of them, the 25%
(N=20) at the 4.8 follow-up time showed onset ofmyxomatous degen-
eration with NYHA I symptoms. Their clinical features were reported in
Table 3b.Table 3a
Clinical characteristics of 90 patients stratiﬁed for NYHA class at preoperative and follow-up (4
Preoperative
Variables NYHA I+II NYHA III
(N=52) (N=38)
Ejection fraction (SD) 57.9±8.97 57.5±8
Left atrium, cm2 (SD) 30.2±9.87 39.4±1
Left ventricular end-diastolic diameter, mm (SD) 55.8±15.8 56±13.
Left ventricular end-diastolic volume, ml (SD) 116±18.5 118±21
Left ventricular end-systolic diameter, mm (SD) 38±5.5 36±5.6
Left ventricular end-systolic volume, ml (SD) 44±10.4 43±6.4
Pulmonary artery systolic pressure, mmHg (SD) 42±8.3 47±6.8
Renal failure 3 (6%) 4 (12.5%
Heart failure 0 (0%) 3 (8%)
Chronic obstructive pulmonary disease 0 (0%) 3 (8%)
Cerebrovascular disease 4 (8%) 8 (25%)
Atrial ﬁbrillation 20 (38%) 19 (50%)
Tricuspid regurgitation grades
Absent 12 (23%) 11 (29%)
Faint 32 (61.5%) 0 (0%)
Moderate 6 (11.5%) 20 (53%)
Severe 2 (4%) 7 (18%)
Pulmonary hypertension 40 (77%) 25 (66%)The second control group included 168 healthy subjects, belonging
to the same ethnic group of patients, in order to include in the study a
very homogenous population. Ethnicity was conﬁrmed, since parents
and grandparents of both patients and controls were born in Western
Sicily, at least two generations. Controls were in good health, evidenced
by their medical history and laboratory data (blood count, erythrocyte
sedimentation rate, blood glucose, blood urea nitrogen, trim electrolyte,
creatinine, CRP, and liver function tests) (see Table 2). Demographic and
clinical featureswere collected, as reported in Table 2. The absence of al-
terations in cardiac structures was conﬁrmed by echocardiography im-
aging examinations. Peripheral blood samples were also collected in
order to assess the genetic background and to perform ELISA assays.
2.3. Ethical study approval
Our study received approval from local ethic committees and all par-
ticipants gave their informed consent. Data were encoded to ensure pa-
tient and control protection. All measurements were performed
without knowledge about nature of material.
2.4. Preoperative and follow-up hemodynamic and anatomical modiﬁca-
tions: Echocardiographic measurements
Precise echocardiographic parameters were collected in the several
steps (preoperative and follow-up times), including left and right ven-
tricular functions and left atrial and ventricular dimensions, mitral gra-
dient, presence and degree of pulmonary hypertension, and tricuspid
insufﬁciency. In addition, other parameters were as follows: ejection
fraction percentage, ventricular size, pulmonary artery systolic pres-
sure, and right atrial pressure. We deﬁned pulmonary hypertension as
a systolic pulmonary pressure N30 mmHg. Tricuspid insufﬁciency was
quantiﬁed through color Doppler method, measuring the area of the
regurgitant volume. Their values were reported in tables as
mean±standard deviation (SD).
2.5. DNA samples and genotyping
DNA case samples were extracted from peripheral blood samples of
all individuals enrolled by using a commercial kit, Gen-Elute Blood Ge-
nomic DNA kit (Sigma, Saint Louis, USA). They were genotyped for the
three SNPs inMMP-2 andMMP-9 genes selected in our study. Informa-
tion about these SNPswas acquired from dbSNP NCBI, the ENSEMBL da-
tabase (http://www.ensembl.org/index.html), and the UCSC Genome.8 years) times
Follow-up (4.8 years)
+IV NYHA I+II NYHA III+IV P1^ P2^
* *
.2 53.9±8.6 55.1±9.67 NS NS
0.3 48±9.7 51.1±13.1 b .001 b .0001
3 52±4.2 52±8.6 NS NS
.1 97±15.6 99±26.5 NS NS
40.4±5.2 39±6.5 NS NS
49±12.8 45±14.7 NS NS
32±5.6 31±4.5 .005 .005
) 0 (0%) 3 (8%)
0 (0%) 3 (8%)
2 (4%) 3 (8%)
2 (4%) 3 (8%)
16 (31%) 12 (31.5%)
0 (0%) 0%
48 (92%) 10 (26%)
4 (8%) 28 (74%)
0% 0%
18 (35%) 22 (58%)
Table 4b
Genotype distribution and allele frequencies of rs3918242(−1562C/T) MMP-9
rs2285053(−735C/T), and rs243865(−1306C/T) MMP-2 polymorphisms in two groups
of 90 MVD patients identiﬁed in according to NYHA classiﬁcation
Candidate
genes
Reference
SNP number
Candidate
SNPs
NYHA I+II
patients
(N=52)
NYHA III+IV
patients
(N=38)
P (cases vs.
cases) (3×2 table)
(2×2 table)
MMP-9 rs3918242 −1562C/C 45 (86%) 25 (66%) .03
−1562C/T 5 (10%) 6 (16%)
−1562T/T 2 (4%) 7 (18%)
−1562C 95 (91%) 56 (74%) .002
−1562T 9 (9%) 20 (26%)
MMP-2 rs2285053 −735C/C 45 (86%) 25 (66%) .002
−735C/T 6 (12%) 7 (18%)
−735 T/T 1 (2%) 6 (16%)
−735C 96 (92%) 57 (75%) .002
−735T 8 (8%) 19 (25%)
Table 3b
Clinical characteristics of 20 individuals with MVD at the 4.8-year follow-up time with
NYHA I symptoms
Variables Values
Ejection fraction (SD) 51±5.4
Left atrium, cm2 (SD) 28.5±3.8
Left ventricular end-diastolic diameter, mm (SD) 52±14.6
Left ventricular end-diastolic volume, ml (SD) 115.3±7.3
Left ventricular end-systolic diameter, mm (SD) 32.6±4.8
Left ventricular end-systolic volume, ml (SD) 36.8±6.1
Pulmonary artery systolic pressure, mmHg (SD) 39.1±8.1
Renal failure 0 (0%)
Heart failure 0 (0%)
Chronic obstructive pulmonary disease 0 (0%)
Cerebrovascular disease 0 (0%)
Atrial ﬁbrillation 5 (25%)
Tricuspid regurgitation grades
Absent 5 (25%)
Faint 15 (75%)
Moderate 0 (0%)
Severe 0 (0%)
Pulmonary hypertension 7 (35%)
^, t test; *NYHA class refers to preoperative time.
365C.R. Balistreri et al. / Cardiovascular Pathology 25 (2016) 362–370Browser website (http://genome.ucsc.edu) and was reported in
Table 1S and 2S (online SupplementaryMaterials; in Table 1S, their biolog-
ical effects are reported; in Table 2S, their frequencies in European popula-
tion are reported). Genotyping was performed using procedures
described in our previous study [23].2.6. MMPs and pro-ANP systemic evaluations
Systemic levels of pro-ANP, MMP-9, and MMP-2 were detected
through ELISA [Pro Human Atrial Natriuretic Peptide kit (Cusabio,
China); Quantikine ELISAHumanMMP-9 Immunoassay kit (RD,Minne-
apolis, USA); Elisa Quantikine Total MMP-2 kit (RD, Minneapolis, USA),
respectively], according to themanufacturer's instructions. To standard-
ize our results, reference preparations of pro-ANP, MMP-9, and MMP-2
were tested in all assays. Results were expressed as picograms per mil-
liliter (pg/ml) for the quantitative values of pro-ANP and as nanograms
per milliliter (ng/ml) for MMP-9 and MMP-2. Detection limits in our
laboratory were 15.6 pg/ml for pro-ANP, 0.014 ng/ml for MMP-2, and
0.156 ng/ml for MMP-9.Table 4a
Genotype distributions and allele frequencies of rs3918242(−1562C/T)MMP-9, rs2285053(−735C/T), and rs243865(−1306C/T)MMP-2 polymorphisms in 90MVDpatients, 80 patien
controls, and 168 healthy controls
Candidate genes Reference SNP number Candidate SNPs Patients
(N=90)
Healthy controls
(N=168)
P1 (cases vs. healthy controls)
(3×2 table) (2×2 table)
Patient controls
(N=80)
P2 (cases vs. patient controls)
(3×2 table) (2×2 table)
MMP9 rs3918242 −1562C/C 70 (78%) 156 (93%) .001 74 (93%) .001
−1562C/T 11 (12%) 9 (5%) 5 (6%)
−1562T/T 9 (10%) 3 (2%) 1 (1%)
−1562C 151 (84%) 321 (95%) .00001 153 (96%) .0008
−1562T 29 (16%) 15 (5%) 7 (4%)
MMP2 rs2285053 −735C/C 70 (78%) 161 (96%) .00001 73 (91%) .05
−735T/C 13 (14%) 6 (3.5%) 5 (6%)
−735T/T 7 (8%) 1 (0.5%) 2 (2%)
−735C 153 (85%) 328 (98%) 1.5e-7 151 (94%) .008
−735T 27 (15%) 8 (2%) 9 (6%)
MMP2 rs243865 −1306C/C 82 (91%) 160 (95%) NS 78 (97%) NS
−1306C/T 6 (7%) 7 (4.5%) 2 (3%)
−1306T/T 2 (2%) 1 (0.5%) 0 (0%)
−1306C 170 (94%) 327 (97%) NS 158 (99%) NS
−1306T 10 (10%) 9 (3%) 2 (1%),2.7. Statistical analysis
All analyses were performed with R and Microsoft Excel software.
Quantitative variables were expressed as mean±SD. t and the
Wilcoxon tests were used to analyze the relationship between quantita-
tive variables. The alleles and genotypes frequency was assessed by
gene count. Data were tested for goodness of ﬁt between observed
and expected genotype frequencies according toHardy–Weinberg equi-
librium, by χ2 tests. Signiﬁcant differences in frequencies, among the
groups, were calculated by χ2 test (3×2, 2×2 tables, where appropri-
ate). In addition, signiﬁcant differences among qualitative variables
were calculated by using χ2 and appropriated tables (3×2; 2×2). The
P value b .05 was considered statistically signiﬁcant. Multiple logistic re-
gression analyses of dominant (major allele homozygotes plus hetero-
zygotes vs. minor allele homozygotes) and recessive (major allele
homozygotes vs. heterozygotes plusminor allele homozygotes)models
were applied to MVD patient group compared with control groups and
between the two patient NYHA groups. Odds ratios (OR), 95% conﬁ-
dence intervals (95% CI), and P values were determined using SPSS
(SPSS Inc., Chicago, IL, USA). A Pb .05 was considered statistically signif-
icant. The signiﬁcant differences of theMVD complications between the
individual carriers of rs3918242 CC+TT and rs2285053 CC+TT geno-
types and no carriers were detected using Fisher's Exact Test and
Pearson's chi-square test. t and the Wilcoxon tests were also used for
calculating signiﬁcant differences of circulating MMP and pro-ANP
levels between the individual carriers of rs3918242 CC+TT and
rs2285053 CC+TT genotypes and no carriers.t
Table 5a
Multiple logistic regression analyses of dominant (major allele homozygotes plus heterozygotes vs. minor allele homozygotes) and recessive (major allele homozygotes vs. heterozygotes
plus minor allele homozygotes) models applied to MVD patient group compared with control groups
MVD cases vs. healthy controls MVD cases vs. patient controls
SNPs Model OR (95% CI) P OR (95% CI) P
rs3918242 Dominant CC+C/T/TT CC+CT/TT
Cases: 81/9 Cases 81/9
Controls:165/3 0.163 (0.043–0.621) .0004 Patient Controls:79/1 0.113 (0.014–0.920) .01
Recessive CC/C/T+TT CC/CT+TT
Cases: 20/70 Cases: 20/70
Controls:12/156 3.71 (1.72–8.017) .0006 Patient Controls:6/74 3.52 (1.337–9.289) .006
rs2285053 Dominant CC+CT/TT CC+CT/TT
Cases: 83/7 Cases: 83/7
Controls:167/1 0.071 (0.008–0.58) .003 Patient Controls:78/2 0.662 (0.453–0.969) .115
Recessive CC/CT+TT CC/CT+TT
Cases: 20/70 Cases: 20/70
Controls:7/161 2.444 (1.817–3.289) b .0001 Patient Controls:7/73 1.513 (1.145–2.000) .01
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3.1. Patients characteristics according to NYHA score
The 90 patients had different symptoms severity in according to
NYHA score (see Tables 3a and 3b). Precisely, 52 patientswere classiﬁed
asNYHA I+II, and 38 patientswere classiﬁed asNYHA III+IV. The com-
parative analysis of their echocardiographic data at preoperative and
4.8-year follow-up times showed a general clinical improvement of he-
modynamic proﬁle of patients. No signiﬁcant difference was observed
in the left ventricular diastolic diameter in two groups at two different
times. The same result was obtained comparing the end-systolic left
ventricular diameter in two groups at two different times (see
Tables 3a and 3b). Furthermore, pulmonary artery pressures were re-
duced in both classes. However, a slight disease progression, mainly
due to the physiological aging process, was observed. For example, in
both the two groups, we observed a signiﬁcant increase in left atrium
medium enlargement at the 4.8 follow-up (see Tables 3a and 3b).
3.2. Genotype distribution and allele frequencies of rs3918242(−1562C/T)
MMP-9, rs2285053(−735C/T)MMP-2, and rs243865(−1306C/T)MMP-2
SNPs in 90 patients, 80 and 168 controls
By comparing genotype distributions and allele frequencies of three
SNPs selected in our study between cases and the two control groups,
signiﬁcant differences were detected, as reported in Table 4a. In partic-
ular, the genotypes of rs3918242(−1562C/T)MMP-9were signiﬁcantly
distributed between cases and healthy controls and cases vs. patient
controls (P=.001 and P=.001, respectively, by χ2 test and 3×2 tables).
Accordingly, the −1562T allele was overrepresented in cases vs. the
two control groups (Yates corrected P=.00001 and P=.0008, respec-
tively, by χ2 test and 2×2 tables). Likewise, the rs2285053(−735C/T)Table 5b
Multiple logistic regression analyses of dominant (major allele homozygotes plus heterozygotes
plus minor allele homozygotes) models applied between the two patients groups
MVD NYHA I+II cases vs. MVD NYHA III+IV cases
SNPs Model
rs3918242 Dominant CC+CT/TT
MVD NYHA I+II case
MVD NYHA III+IV ca
Recessive CC/CT+TT
MVD NYHA I+II case
MVD NYHA III+IV ca
rs2285053 Dominant CC+CT/TT
MVD NYHA I+II case
MVD NYHA III+IV ca
Recessive CC/CT+T
MVD NYHA I+II case
MVD NYHA III+IV caMMP-2 SNP showed very signiﬁcant differences in genotype and allele
frequencies, by comparing its values between cases vs. healthy controls
(P=.00001 and Yates corrected P=1.5e-7, by χ2 test and appropriate
tables) and cases vs. patient controls (P=.05 and Yates corrected
P=.008, by χ2 test and appropriate tables). In contrast, no signiﬁcant
differences were observed in genotype distributions and allele frequen-
cies of rs243865(−1306C/T) MMP-2 SNP between cases vs. healthy
controls and cases vs. patient controls.
These resultswere conﬁrmed by logistic regression analyses of dom-
inant and recessive models performed between patient and control
groups (Table 5a). Interestingly, the data obtained through comparisons
between cases and patient and healthy controls for dominant model
and recessive models evidenced that patients carrying of the minor al-
leles (−1562T and −735T) of rs3918242(−1562C/T) MMP-9 and
rs2285053(−735C/T) MMP-2 SNPs were signiﬁcantly susceptible for
MVD disease in recessive models (see data reported Table 5a).
3.3. Genotype distribution and allele frequencies of rs3918242(−1562C/T)
MMP-9 and rs2285053(−735C/T) MMP-2 SNPs in two NYHA patient
groups and 20 NYHA I subjects
The data's analysis of genotype distributions and allele frequencies
of two SNPs in MMP-9 and MMP-2 genes between 52 NYHA I+II and
38 NYHA III+IV patients evidenced signiﬁcant differences (see
Table 4b). The genotypes of rs3918242(−1562C/T)MMP-9were signif-
icantly distributed between52NYHA I+II and 38NYHA III+IVpatients
(P=.03, by χ2 test and 3×2 tables). Accordingly, the−1562T allelewas
overrepresented in 38 NYHA III+IV patients vs. the 52 NYHA I+II pa-
tients (20 vs. 9, Yates corrected P=.002 by χ2 test and 2×2 tables). In
addition, the rs2285053(−735C/T)MMP-2 SNP showed very signiﬁcant
differences in genotype and allele frequencies, by comparing its values
between 52 NYHA I+II and 38 NYHA III+IV patients. In particular,vs. minor allele homozygotes) and recessive (major allele homozygotes vs. heterozygotes
OR (95% CI) P
s: 50/2
ses: 31/7 2.778 (0.808–9.547) .02
s: 7/45
ses: 13/25 1.82 (1.161–2.854) .01
s: 51/1
ses: 32/6 9.563 (1.099–83.183) .02
s: 6/46
ses: 13/25 3.98 (1.349–11.778) .009
Table 6a
Circulating levels of MMP-2 and MMP-9 and pro-ANP at enrolment and 4.8-year follow-up in NYHA patients, 168 healthy controls, and 20 individuals with MVD at 4.8-year follow-up stratiﬁed for the genotypes of rs3918242C/T MMP-9 SNP
rs3918242CT+TT
NYHA I+II cases
rs3918242CC
NYHA I+II cases
P rs3918242CT+TT
NYHA III+IV cases
rs3918242CC
NYHA III+IV cases
P rs3918242CT+TT
6 follow-up patients
rs3918242CC
14 follow-up patients
P rs3918242CT+TT
healthy controls
rs3918242CC
healthy controls
P
N=7 N=45 N=13 N=25 N=6 N=14 N=12 N=156
ANP at 1 time 498±51 415±82 .002 525±87 459±69 .01 160±59 130±47 NS 16±8.6 15.2±7.4 NS
ANP at follow-up 547±32 456±64 b .0001 593±59 486±45 b .0001 296±69 198±32 .01 19±13.2 17±13 NS
MMP-9 at 1 time 58±18 41±12 .02 59±11 43±12 .0002 38±19 22±15 .05 30±11 18±13 .001
MMP-9 at follow-up 66±15 52±9 .02 64±8 56±7 .003 56±18 41±13 .05 39±12 23±10 b .0001
Table 6b
Circulating levels of MMP-2 and MMP-9 and pro-ANP at enrolment and 4.8-year follow-up in NYHA patients, 168 healthy controls, and 20 individuals with MVD at 4.8-year follow-up stratiﬁed for the genotypes of rs2285053C/T MMP-2 SNP
rs2285053CT+TT
NYHA I+II cases
rs2285053CC
NYHA I+II cases
P rs2285053CT+TT
NYHA III+IV cases
rs2285053CC
NYHA III+IV cases
P rs2285053CT+TT 6
follow-up patients
rs2285053CC 14
follow-up patients
P rs2285053CT+TT
healthy controls
rs2285053CC
healthy controls
P
N=7 N=45 N=13 N=25 N=6 N=14 N=7 N=161
ANP at 1 time 501±47 380±61 b .0001 565±54 460±61 .008 158±57 128±44 NS 17±6 14±8 NS
ANP at follow-up 575±28 472±71 b .0001 601±63 479±39 b .0001 287±63 195±31 .007 18±10 16±11 NS
MMP-2 at 1 time 59±18 40±15 .01 60±10 50±9 .003 39±20 25±16 .01 27±10 19±9 .01
MMP-2 at follow-up 69±15 50±11 .007 71±14 58±11 .004 55±20 33±12 .02 40±11 22±13 .0002
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Table 7a
Prevalence expressed in percentages of MVD complications at enrolment and 4.8-year follow-up in NYHA patients and 20 individuals with MVD at 4.8-year follow-up stratiﬁed for the
genotypes of rs3918242C/T MMP-9 SNP
rs3918242CT+TT
NYHA I+II cases
rs3918242CC
NYHA I+II cases
P rs3918242 CT+TT
NYHA III+IV cases
rs3918242CC
NYHA III+IV cases
P rs3918242CT+TT 6
follow-up patients
rs3918242CC 14
follow-up patients
P
N=7 N=45 N=13 N=25 N=6 N=14
Pulmonary hypertension at 1time 4 (57%) 36 (80%) .007 6 (46%) 19 (76%) NS 0 (0%) 0 (0%) NS
Pulmonary hypertension at follow-up 7 (100%) 11 (24%) .0002 13 (100%) 9 (36%) .00009 6 (100%) 1 (7%) .001
Tricuspid regurgitation at 1 time 7 (100%) 33 (73%) NS 13 (100%) 14 (56%) .00004 0 (0%) 0 (0%) NS
Tricuspid regurgitation at follow-up 7 (100%) 45 (100%) 1e-8 13 (100%) 25 (100%) .0003 6 (100%) 14 (100%) .03
Cerebrovascular disease at 1 time 2 (28%) 0 (0%) .01 7 (100%) 1 (4%) .000002 0 (0%) 0 (0%)
Cerebrovascular disease at follow-up 0 (0%) 0 (0%) NS 3 (23%) 0 (0%) .007 0 (0%) 0 (0%) NS
Heart failure at 1tme 2 (28%) 0 (0%) .01 3 (23%) 0 (0%) .007 0 (0%) 0 (0%) NS
Heart failure at follow-up 3 (43%) 0 (0%) .001 3 (23%) 0 (0%) .007 0 (0%) 0 (0%) NS
368 C.R. Balistreri et al. / Cardiovascular Pathology 25 (2016) 362–370the allele−735T was overrepresented in 38 NYHA III+IV patients vs.
the 52 NYHA I+II patients (19 vs. 8, Yates corrected P=.002, by χ2
test and 2×2 tables).
Furthermore, we observed that rs3918242(−1562C/T)MMP-9 and
rs2285053(−735C/T) MMP-2 SNPs in two NYHA patient groups con-
ferred a higher risk for MVD in both dominant and recessive models
(see Table 5b).
Concerning the20 individualswithNYHA I symptoms,we interestingly
observed that 6 (30%) were carriers of both−1562C/T+−1562TT and
−735C/T+−735T/T genotypes of rs3918242(−1562C/T) MMP-9 and
rs2285053(−735C/T)MMP-2 SNPs (data not shown).
3.4. Associations of rs3918242(−1562C/T)MMP-9 and rs2285053(−735C/T)
MMP-2 SNPs with the MVD severity, prevalence of its complications at short
and long times, and outcome
Asdescribed in thepreviousparagraphs, the two rs3918242(−1562C/T)
MMP-9 and rs2285053(−735C/T)MMP-2 SNPs were signiﬁcantly over-
represented in the patients and associated with high MVD risk. In par-
ticular, in the two NYHA patient's groups, these SNPs conferred a very
signiﬁcant high risk in both dominant and recessive models (see
Table 5b). In the light of these results, we also detected eventual associ-
ations of these SNPs with severity and prevalence of disease complica-
tions at short and long times and consequently with its outcome. To
this aim, circulating levels of pro-ANP and the two MMP enzymes
were ﬁrstly quantiﬁed at the two (enrolment and 4.8 follow-up)
times in the plasma samples from the three groups studied, and subse-
quently, their mean values were stratiﬁed for the rs3918242(−1562C/
T) MMP-9 and rs2285053(−735C/T) MMP-2 SNP genotypes (see
Tables 6a and 6b). The data obtained conﬁrmed that the patient carriers
of rs3918242 CC+TT and rs2285053 CC+TT genotypes had signiﬁcant
high levels of circulating pro-ANP and the two enzymes at two times,
but particularly at 4.8 follow-up, than patient carriers of rs3918242 CC
and rs2285053 CC genotypes (see Tables 6a and 6b, which report levels
of thesemolecules inmean values±DS and P values detected by using tTable 7b
Prevalence expressed in percentages of MVD complications at enrolment and 4.8-year follow-
genotypes of rs2285053C/T MMP-2 SNPs
rs2285053CT+TT
NYHA I+II cases
rs2285053CC
NYHA I+II cases
P rs2285
NYHA
N=7 N=45 N=13
Pulmonary hypertension at 1time 4 (57%) 36 (80%) .007 6 (46
Pulmonary hypertension at follow-up 7 (100%) 11 (24%) .0002 13 (10
Tricuspid regurgitation at 1 time 7 (100%) 33 (73%) NS 13 (10
Tricuspid regurgitation at follow-up 7 (100%) 45 (100%) 1e-8 13 (10
Cerebrovascular disease at 1 time 2 (28%) 0 (0%) .01 7 (10
Cerebrovascular disease at follow-up 0 (0%) 0 (0%) NS 3 (23
Heart failure at 1tme 2 (28%) 0 (0%) .01 3 (23
Heart failure at follow-up 3 (43%) 0 (0%) .001 3 (23test). In particular, higher levels of thesemoleculeswere assessed in pa-
tient carriers bearing the rs3918242 CC+TT and rs2285053 CC+TT ge-
notypes and belonging at NYHA III and IV classes. Similar results were
obtained by stratifying for these genotypes the 20 individuals, who at
4.8 follow-up showed MVD onset with NYHA I symptoms, even if
their number was very small (see Tables 6a and 6b).
Furthermore, in the patient carriers of rs3918242 CC+TT and
rs2285053 CC+TT genotypes, we observed a signiﬁcant prevalence
(expressed in percentage, %; see Tables 7a and 7b, which show the per-
centage values of each complications at the two times and P values) at
both enrolment and 4.8 follow-up times of MVD complications, includ-
ing pulmonary hypertension, tricuspid regurgitation, cerebrovascular
disease, and heart failure. Precisely, we assessed that, at 4.8 follow-up
time, all patients of both NYHA classes carriers of rs3918242 CC+TT
and rs2285053 CC+TT genotypes [7 (100%) and 13 (100%); see
Table 4b] showed pulmonary hypertension and tricuspid regurgitation
(even if of faint and moderate grades). Differently, few cases of both
NYHA classes and with rs3918242 CC and rs2285053 CC genotypes
had these MVD complications. Furthermore, the 28% of NYHA I+II pa-
tients at enrolment time with rs3918242 CC+TT and rs2285053
CC+TT genotypes developed cerebrovascular disease, but not at 4.8
follow-up. The 28% and 43% of NYHA I+II cases with rs3918242
CC+TT and rs2285053 CC+TT genotypes also had heart failure. No
cases of cerebrovascular disease and heart failure were observed at
the two times in group of NYHA I+II patients with rs3918242 CC and
rs2285053 CC genotypes. Similar data were detected in NYHA III+IV
patients at two times with rs3918242 CC+TT and rs2285053 CC+TT
genotypes (23%) (see Tables 7a and 7b). In addition, the 23% of patients
of NYHA III+IV class with rs3918242 CC+TT and rs2285053 CC+TT
genotypes displayed a severe clinical status with heart failure at the
two times. Likewise, the 6 individuals with rs3918242 CC+TT
and rs2285053 CC+TT genotypes of the 20 subjects, who at 4.8
follow-up showed MVD onset with NYHA I symptoms, showed all pul-
monary hypertension and tricuspid regurgitation of faint grades (see
Tables 7a and 7b).up in NYHA patients and 20 individuals with MVD at 4.8-year follow-up stratiﬁed for the
053CT+TT
III+IV cases
rs2285053CC
NYHA III+IV cases
P rs228505CT+TT 6
follow-up patients
rs2285053CC 14
follow-up patients
P
N=25 N=6 N=14
%) 19 (76%) NS 0 (0%) 0 (0%) NS
0%) 9 (36%) .00009 6 (100%) 1 (7%) .001
0%) 14 (56%) .00004 0 (0%) 0 (0%) NS
0%) 25 (100%) .0003 6 (100%) 14 (100%) .03
0%) 1 (4%) .000002 0 (0%) 0 (0%)
%) 0 (0%) .007 0 (0%) 0 (0%) NS
%) 0 (0%) .007 0 (0%) 0 (0%) NS
%) 0 (0%) .007 0 (0%) 0 (0%) NS
369C.R. Balistreri et al. / Cardiovascular Pathology 25 (2016) 362–3703.5. Levels of systemic MMP-2 and MMP-9 and pro-ANP molecules in the
healthy control group stratiﬁed for rs3918242 CC+TT and rs2285053
CC+TT genotypes
We also compared the systemic levels of MMP-2 and MMP-9 and
pro-ANP molecules in control carriers versus no control carriers, as re-
ported in Tables 6a and 6b. As shown in these tables, these comparisons
demonstrated signiﬁcant differences of two enzymes at two times, but
not certainly for pro-ANP. In particular, carriers of rs3918242 CC+TT
and rs2285053 CC+TT genotypes showed signiﬁcant levels of systemic
MMP-2 and MMP-9 than no control carriers.
4. Discussion
In this study, we focused our attention in evaluating the potential as-
sociations of rs3918242(−1562C/T MMP-9), rs243865(−1306C/T
MMP-2), and rs2285053(−735C/T MMP-2) MMP-9 and MMP-2 func-
tional gene SNPs with susceptibility, symptom severity, and short- and
long-term (at 4.8 years) complications of degenerative MVD forms.
Our interest is supported by experimental studies on animal models
and humans, which have suggested a key role of MMPs in their onset
and progression [7–15]. However, in literature, there are few data
[16,17] showing associations of SNPs inMMP genes withMVD suscepti-
bility. Thus, our study represents the ﬁrst report that analyzed, in a per-
spectivemanner, associations of functional genetic variants in theMMP-
2 and MMP-9 genes not only with MVD risk but also with its severity
and complications, as well as with long-term outcome after surgical ap-
proaches (i.e., mitral valve replacement or plastic surgery). We also
used a particular study's strategy characterized by selecting a homoge-
nous group of patients (N=90), all affected by myxomatous degenera-
tion and at late stage of disease, when they were referred for mitral
valve surgery (repair or replacement), and a control group of patients
(N=80), showing no degenerative MVD at the time of its enrollment
but with a manifested myxomatous mitral degeneration at the 4.8
follow-up time in 20% of its components with NYHA I symptoms.
By analyzing the data of genotyping, we observed that the
rs3918242(−1562C/T MMP-9) and rs2285053(−735C/T MMP-2)
SNPs, determining an increased expression of both gelatinases, were
signiﬁcantly represented in cases respect to controls (see Table 4a).
We also assessed that cases with rs3918242 CT+TT MMP-9 and
rs2285053CT+TT genotypes had signiﬁcant high risk of MVD in reces-
sive model (see Table 5a). In addition, the 90 cases divided in two
groups (52 and 38, respectively) with NYHA I+II and NYHA III+IV
symptomgrades also showed signiﬁcant differences in genotype and al-
lele frequencies of two SNPs and a very signiﬁcant high risk for MVD
both in dominant and recessive models (see Table 5b). Concerning the
20 individuals of patient control group with MVD and NYHA I symp-
toms at 4.8-year follow-up, we interestingly observed that the 6 (30%)
were carriers of both−1562C/T+−1562TT and−735C/T+−735T/T
genotypes of rs3918242(−1562C/T) MMP-9 and rs2285053(−735C/
T)MMP-2 SNPs (data not shown).
In the light of these relevant results obtained, we also assessed the
associations of these SNPs with the severity and prevalence of short-
and long-time complications (at enrolment and at 4.8-year follow-up)
and consequently with MVD outcome. To this aim, we ﬁrstly quantiﬁed
the systemic levels of two gelatinases in the plasma samples from cases
and two control groups and subsequently we stratiﬁed them for the ge-
notypes. By comparing the systemic amounts,we found that cases of the
two NYHA symptoms classes carrying rs3918242 CT+TT MMP-9 and
rs2285053CT+TT genotypes showed higher circulating levels of
MMP-9 and MMP-2 enzymes at the two times (enrolment and 4.8
follow-up) than cases of the same NYHA classes and the healthy con-
trols carrying rs3918242CC MMP-9 and rs2285053CC genotypes (see
Tables 6a and 6b). Thus, the interesting results obtained also led us to
suggest that the SNPs studied can modulate risk, onset, and severity of
symptoms shown by patient's population and detected in accordanceto NYHA degrees as established by guidelines. Accordingly, cases of
the two NYHA symptom classes carrying rs3918242 CT+TT MMP-9
and rs2285053CT+TT genotypes also had very signiﬁcant circulating
pro-ANP levels at the two times compared to cases of the same NYHA
classes and the healthy controls carrying rs3918242CC MMP-9 and
rs2285053CC genotypes (see Tables 6a and 6b). Surprisingly, signiﬁcant
differences in the circulating levels of two enzymes were also assessed
in 6 individuals with MVD at 4.8-year follow-up carrying rs3918242
CT+TT MMP-9 and rs2285053CT+TT genotypes than the 14 subjects
with MVD at 4.8-year follow-up carrying rs3918242CC MMP-9 and
rs2285053CC genotypes (see Tables 6a and 6b).
Furthermore, in all patient (52 and 32 NYHA patients) carriers of
rs3918242 CC+TT and rs2285053 CC+TT genotypes, we observed a
signiﬁcant prevalence at both enrolment and 4.8 follow-up times of
MVD complications, including pulmonary hypertension, tricuspid re-
gurgitation, cerebrovascular disease, and heart failure. In particular,
the cases of NYHA III+IV class with rs3918242 CC+TT and
rs2285053 CC+TT genotypes displayed a more severe clinical status
at the two times. Interestingly, all 6 individuals with MVD at 4.8-year
follow-up carrying rs3918242 CT+TT MMP-9 and rs2285053CT+TT
genotypes also showed pulmonary hypertension and tricuspid regurgi-
tation (of faint grades) than the 14 subjects with MVD at 4.8-year
follow-up carrying rs3918242CC MMP-9 and rs2285053CC genotypes,
even if these last had all tricuspid regurgitation, but pulmonary hyper-
tension was found only in 1 of them.
In accordance of the data assessed in cases, we compared systemic
levels of MMP-2 and MMP-9 and pro-ANP in healthy group, stratiﬁed
for the genotypes of MMP-9 and MMP-2 SNPs. Controls bearing
rs3918242 CT+TT MMP-9 and rs2285053CT+TT genotypes showed
higher levels of two enzymes than control carriers of rs3918242CC
MMP-9 and rs2285053CC genotypes. These results are in agreement
with the data of a previous study performed on another cardiovascular
disease, such as sporadic thoracic aneurysm [23,24].
5. Limitations and conclusions
In complex, the results obtained suggest, for theﬁrst time, signiﬁcant
associations ofMMP-9 andMMP-2 genetic variantswith the susceptibil-
ity of degenerativeMVD forms, their severity, and their short- and long-
term complications. Furthermore, cases bearing the rs3918242 CT+TT
MMP-9 and rs2285053CT+TT genotypes, even if underwent to mitral
valve replacement, also showed a worse outcome at long term (4.8
years).
Certainly, future and additionalmore large studies are needed to val-
idate our results, since our sample size was relatively small. This might
permit to open new perspectives in the management and outcome of
degenerative MVD forms, using these genetic variants and MMP-9 and
MMP-2 as innovative biomarkers and targets for developing personal-
ized treatments. Revealing the role of MMP-9 and MMP-2 in degenera-
tive MVD forms may serve as a starting point for future studies leading
to a better understanding of the pathophysiological basis and perhaps
effective treatment of these human diseases. As result, themanagement
and outcome strategies for themedical and surgical treatment of degen-
erative MVD forms might become gene tailored. In addition, these in-
sights might lead to propose new treatment options such as the use of
agonist and/or antagonists of TGF-β pathways andmonoclonal antibod-
ies against MMP-2 and MMP-9. These treatments might likely have
more advantage effects with respect to those mediated by diuretics,
calcium-channel blocker, angiotensin receptor blockers, ACE inhibitors,
statins, and antidiabetic and antiplatelet agents, which seem to inﬂu-
ence, in different ways, the MMP pattern with beneﬁcial effects on car-
diovascular outcome, as recently reported by Hopps and Caimi [25]. As
regards, we assessed in this study whether these drugs were able to
limit severity and complications at long term (4.8 years) in cases bear-
ing high responder genotype. No signiﬁcant data were obtained (data
not shown). This led us to suppose that a more speciﬁc therapy might
370 C.R. Balistreri et al. / Cardiovascular Pathology 25 (2016) 362–370be necessary to reduce the effects of genetic propensity, and probably a
better understanding of MVD pathophysiology might be useful. As con-
sequence, future studies and additional efforts are imperative as well as
a combination of analysis based on genetic, transcriptomic, proteomic,
and epigenomic evaluations. Epigenomic, transcriptomic, and proteo-
mic approaches might particularly provide valuable insights about dis-
ease pathobiology, although it is very difﬁcult obtaining human tissue
valve samples and appropriate controls.
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